ST
AST

Spot Trading’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Spot Trading’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-13,153
Closed -$47.6K – 4200
2016
Q1 		$62K Buy
13,153
+3,670
+39% +$14.2K ﹤0.01% 2751
2015
Q4 		$37K Buy
+9,483
New +$43.7K ﹤0.01% 3125

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Spot Trading's AST Position: Q2 2016 in Review

Spot Trading sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2016, closing a stake of 13,153 shares — an estimated $47.6K sold.

Spot Trading first reported a position in AST in Q4 2015 and held it in 2 quarters. The position peaked at $62K in Q1 2016. 66 funds tracked by Wall St. Rank hold AST as of Q2 2016.

  • Spot Trading reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2016 after selling out during the quarter.
  • Spot Trading sold 13,153 Asterias Biotherapeutics Inc. Series A shares in Q2 2016, an estimated $47.6K.
  • Spot Trading first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2015 and held it in 2 quarters.
  • Spot Trading's Asterias Biotherapeutics Inc. Series A position peaked at $62K in Q1 2016.
  • 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2016.

Based on Spot Trading's 13F filing for Q2 2016, filed 2 Aug 2016.